Angiotensin-neprilysin inhibition in acute decompensated heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema. RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, one-third of patients enrolled did not have a history of HF and just more than half had no previous ACEI or ARB use.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In-hospital initiation of sacubitril-valsartan resulted in a significantly greater proportional reduction in NT-proBNP compared with enalapril at weeks 4 and from baseline (mean time-averaged change in NT-proBNP, −46.7% vs 25.3%).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“This change was consistent across all subgroups, including those without previous HF and those who were RASi-naive.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In the PIONEER-HF study it was noted that in patients admitted with acute decompensated HF and reduced ejection fraction, 65% had a history of HF but only 10% were receiving an MRA at the time of admission.8”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citation
Cited by
Items 501–600 of 999
Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice
Sinagra, G., Pagura, L., Stolfo, D., Fabris, E., Savarese, G., Rapezzi, C., Ferrari, R., & Merlo, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.017 · Cited by 12
Medvedovsky, A. T., Haberman, D., Ibrahimli, M., Tonchev, I., Rashi, Y., Peretz, A., Shimoni, S., Tuvali, O., Danenberg, H. D., Beeri, R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245849 · Cited by 13
Hyponatraemia in heart failure: time for new solutions?
Kapłon‐Cieślicka, A., Soloveva, A. E., Mareev, Y., Cabac‐Pogorevici, I., Verbrugge, F. H., & Vardas, P. E. (2021) · Heart · doi:10.1136/heartjnl-2021-320277 · Cited by 11
Lin, J., Zhou, J., Xie, G., & Liu, J. (2021) · Medicine · doi:10.1097/md.0000000000028231 · Cited by 9
Xu, X., Li, Y., Shi, S., Lv, J., Wang, Y., Zheng, H., Mao, X., Wu, H., Zhang, B., & Song, Q. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.899235 · Cited by 11
Ostrominski, J. W., & Vaduganathan, M. (2022) · Clinical Cardiology · doi:10.1002/clc.23849 · Cited by 11
Reina‐Couto, M., Silva-Pereira, C., Pereira‐Terra, P., Quelhas‐Santos, J., Bessa, J., Serrão, P., Afonso, J., Martins, S., Dias, C. C., Morato, M., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.965611 · Cited by 10
Jia, R., Ji, Y., & Sun, D. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113701 · Cited by 10
Shen, J., Fan, Z., Wu, C., Qi, G., Cao, Q.-Y., & Xu, F. H. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5009289 · Cited by 9
Silverdal, J., Bollano, E., Henrysson, J., Basic, C., Fu, M. L. X., & Sjöland, H. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14214 · Cited by 9
Gjyriqi, G., York, M., Abuazzam, F., Herzog, C. A., Bangalore, S., Lo, K. B., Sidhu, M. S., Vaduganathan, M., Rangaswami, J., & Mathew, R. O. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.10.432 · Cited by 9
Innovations in medical therapy of heart failure with reduced ejection fraction
Mercurio, V., Ambrosio, G., Correale, M., Dini, F. L., Ghio, S., Nodari, S., Palazzuoli, A., Ruocco, G. M., Pedrinelli, R., Mercuro, G., et al. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001413 · Cited by 10
Retrospective Analysis of SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction
Clemmer, J. S., Ward, T. J., & Lirette, S. T. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14347 · Cited by 9
An update on the use and discovery of prognostic biomarkers in acute decompensated heart failure
Darden, D. J., Nishimura, M., Sharim, J., & Maisel, A. S. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1671188 · Cited by 9
GDMT for heart failure and the clinician's conundrum
Samarendra, P. (2019) · Clinical Cardiology · doi:10.1002/clc.23268 · Cited by 9
Gu, W., Xu, C., Zhao, L., & Li, Z. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-21-355 · Cited by 10
Borovac, J. A. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2039626 · Cited by 10
Acute decompensation of heart failure: state of the problem
Жиров, И. В., Николаевна, Н. С., & Tereshchenko, S. N. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.09.201839 · Cited by 9
Kim, I., & Yoo, B. (2022) · Diagnostics · doi:10.3390/diagnostics12061366 · Cited by 12
Acute Cardiorenal Syndrome: An Update
Sohal, S., Uppal, D., Mathai, S. V., Wats, K., & Uppal, N. N. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000532 · Cited by 13
Shen, X., Chen, G., Liu, M., Jiang, Y., Xu, Y., Ge, Z., Tao, Z., Dong, N., Liao, J., Yu, L., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291754 · Cited by 8
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Rimskaya, E. M., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2024) · Eurasian heart journal · doi:10.38109/2225-1685-2024-2-6-76 · Cited by 8
Boehmer, A. A., Schubert, T., Rothe, M., Keim, C., Wiedenmann, L. C., Ruckes, C., von Stülpnagel, L., Theurl, F., Schreinlechner, M., Dobre, B. C., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033538 · Cited by 9
Hishida, E., & Nagata, D. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000541939 · Cited by 10
Mezcua, A. R., Januzzi, J. L., Pavón, F. J., Rodríguez‐Capitán, J., López-Garrido, M. A., Álvarez, C. C., Robles-Mezcua, M., Gutiérrez‐Bedmar, M., Couto‐Mallón, D., Rueda-Calle, E. C., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117874 · Cited by 10
Essandoh, K., Eramo, G. A., Subramani, A., & Brody, M. J. (2025) · Biophysical Journal · doi:10.1016/j.bpj.2025.02.010 · Cited by 9
Current Practice of Guideline-Directed Medical Therapy After Acute Heart Failure Hospitalization
Kanaoka, K., Iwanaga, Y., Takegawa, K., Fujimoto, W., Nishioka, Y., Myojin, T., Okada, K., Noda, T., Imamura, T., & Miyamoto, Y. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.01.015 · Cited by 9
Michieli, L. D., Lupi, A., Sinigiani, G., Tietto, A., Salvalaggio, A., Branca, A., Pozzo, S. D., Rizzo, S., Cecchin, D., Marra, M. P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103481 · Cited by 10
Naidu, A. S., Ambrosy, A. P., Cotter, G., Bocchi, E. A., Butler, J., Chioncel, O. D., Davison, B. A., Dzudié, A., Freund, Y., Fudim, M., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15389 · Cited by 10
Self-citationAcute Heart Failure Care – a Consensus Series of an International Experts' Group
Cotter, G., Biegus, J., Fudim, M., Miró, Ò., Ambrosy, A. P., Pagnesi, M., Chioncel, O. D., Davison, B. A., Freund, Y., Bocchi, E. A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70057 · Cited by 11
Self-citationLuedde, M., Agewall, S., Ambrosio, G., Bayés‐Genís, A., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70069 · Cited by 11
Ying-hao, S. U. N., Li, J., Li, G., Fan, R., & Luo, J. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28899 · Cited by 12
Yoshikawa, T. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.02.008 · Cited by 10
Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update
Hellenkamp, K., Nolte, K., & von Haehling, S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2047647 · Cited by 9
Morillas, H., Galcerá, E., Alania-Torres, E., Seller, J., Larumbe, A., Núñez, J. E., & Valle, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2304139 · Cited by 9
Bhat, T. S., Hafeez, I., Tak, S. F., Mattoo, A., Patigaroo, A. R., Khan, A., Lone, A. A., & Beig, J. R. (2022) · Indian Heart Journal · doi:10.1016/j.ihj.2022.04.003 · Cited by 11
Witte, K. K., Wachter, R., Senni, M., Bělohlávek, J., Straburzyńska‐Migaj, E., Fonseca, C., Lonn, E., Noè, A., Schwende, H., Butylin, D., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14166 · Cited by 8
Yang, H., Xu, X.-D., Shaikh, A. S., & Zhou, B.-T. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221140575 · Cited by 8
Lee, K., Noh, J. H., Park, S., Choi, K. M., Kang, S., Won, K. C., Cho, H., & Moon, M. K. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0028 · Cited by 8
Gu, J., Wang, Y., Wang, C., & Zhang, J. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.03.019 · Cited by 10
Kotak, S., Hassan, W., Mehmood, M., Kumar, U., Sagreeka, F. N. U., Karishma, F., Kumari, P., Pirya, F., Saquib, J., Iqbal, A., et al. (2023) · Cureus · doi:10.7759/cureus.46547 · Cited by 8
Kodsi, M. H., Makarious, D., Gan, G. C. H., Choudhary, P., & Thomas, L. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14555 · Cited by 10
Aoyama, D., Miyazaki, S., Amaya, N., Tama, N., Hasegawa, K., Nomura, R., Tsuji, T., Nakano, A., Uzui, H., & Tada, H. (2023) · Heart and Vessels · doi:10.1007/s00380-023-02329-7 · Cited by 8
Kalantari, S., Oren, D., Medvedofsky, D. A., Narang, A., Imamura, T., Tayazime, S., Kim, G. H., Raikhelkar, J., SAYER, G. T., Lang, R. M., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.09.110 · Cited by 8
Olivella, A., Bonet, L. A., Moliner, P., Coloma, E., Martínez‐Rubio, A., Bermejo, M. P., Boixeda, R., Cediel, G., Méndez, A. B., & Fácila, L. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14647 · Cited by 8
Pascual-Figal, D. A., Villota, J. N., Pérez‐Martínez, M. T., González‐Juanatey, J. R., Urquía, M. T., Llàcer, P., González-Martín, J., Villar, S., Soler, M., Mirabet, S., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3300 · Cited by 14
Kaul, U., Das, M. K., Agarwal, R., Bali, H. K., Bingi, R., Chandra, S., Chopra, V., Dalal, J. J., Jadhav, U., Jariwala, P. V., et al. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.09.007 · Cited by 9
Tan, N. Y. L., Deng, Y., Yao, X., Sangaralingham, L. R., Shah, N. D., Rule, A. D., Burnett, J. C. J., Dunlay, S. M., & Sangaralingham, S. J. (2021) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2020.10.008 · Cited by 10
Gori, M., Januzzi, J. L., D’Elia, E., Lorini, F. L., & Senni, M. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.25 · Cited by 8
Chen, Y., Hang, C., Su, C.-H., Wu, P., Chen, H., Fang, H., Fang, Y., Cheng, C., Fu, M., & Chen, S. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.55119 · Cited by 8
Bravo, M. J.-B., Valle, A., Ordás, J. G., Díaz, S. D. P., Pereda, D. C., Climent, H. M., Claret, R. B., Moya, J. S., Gómez, J. L. Z., & Salinas, G. L. A. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001111 · Cited by 9
New Drugs for Heart Failure: What is the Evidence in Older Patients?
Orso, F., Herbst, A., Pratesi, A., Fattirolli, F., Ungar, A., Marchionni, N., & Baldasseroni, S. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.011 · Cited by 10
Fucili, A., Cimaglia, P., Severi, P., Giannini, F., Boccadoro, A., Micillo, M., Rapezzi, C., Tavazzi, L., & Ferrari, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194325 · Cited by 8
Villevalde, S. V., & Soloveva, A. E. (2021) · Kardiologiia · doi:10.18087/cardio.2021.12.n1860 · Cited by 8
Drug Treatment of Heart Failure in Children: Gaps and Opportunities
Weisert, M., Su, J. A., Menteer, J., Shaddy, R. E., & Kantor, P. F. (2022) · Pediatric Drugs · doi:10.1007/s40272-021-00485-9 · Cited by 9
What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
Badreldin, H. A., Aldosari, N., Alnashwan, L. I., Almutairi, T., Yousif, N., Sulaiman, K. A. A., Aljuhani, O. A., Hafiz, A. M., & Alshaya, O. A. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9020054 · Cited by 8
Greene, S. J., Lautsch, D., Gaggin, H. K., Djatche, L. M., Zhou, M., Song, Y., Signorovitch, J., Stevenson, A. S., Blaustein, R. O., & Butler, J. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.016 · Cited by 8
Chapman, B., Hellkamp, A. S., Thomas, L. E., Albert, N. M., Butler, J., Patterson, J. H., Hernandez, A. F., Williams, F. B., Shen, X., Spertus, J. A., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022889 · Cited by 8
Self-citationHernández, A. V., Pasupuleti, V., Scarpelli, N., Malespini, J. E., Banach, M., & Bielecka-Dabrowa, A. M. (2023) · Archives of Medical Science · doi:10.5114/aoms/159113 · Cited by 13
Becher, P. M., Savarese, G., Benson, L., Dahlström, U., Karlström, P., Mol, P. G. M., Metra, M., Bhatt, D. L., Pitt, B., & Lund, L. H. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad012 · Cited by 9
Effects of Sacubitril–Valsartan in Patients With Various Types of Heart Failure: A Meta-analysis
Zhang, H., Huetteman, A. T., Reyes, E., & Appelbaum, J. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001421 · Cited by 10
Wang, X., Pu, J., Wang, G., Xu, H. M., Liu, L., Li, Z., Qin, R., Zhao, X., Li, M., Hao, Z., et al. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03374-w · Cited by 9
Sandeep, B., Huang, X., Jiang, F., & Xiao, Z. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102464 · Cited by 9
Miric, D., Baković, D., Eterović, D., Sorić, T., Čapkun, V., Vuković, I., Duplančić, D., & Barac, A. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10041-4 · Cited by 8
BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era
Sbolli, M., & deFilippi, C. R. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01398-8 · Cited by 9
Mareev, Y. V., & VIu, M. (2021) · Kardiologiia · doi:10.18087/cardio.2021.6.n1678 · Cited by 10
Sacubitril/Valsartan in Dialysis Patients: Update on Current Perspectives
Spatola, L., Zeiler, M., & Granata, A. R. M. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07481-w · Cited by 7
Rindone, J. P., & Mellen, C. K. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03686-6 · Cited by 7
Early Initiation of Guideline-Directed Medical Therapy for Heart Failure After Cardiac Surgery
Schwann, A. N., Jaffe, L. M., Givertz, M. M., Wood, K. L., & Engelman, D. T. (2024) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2024.05.034 · Cited by 7
Marques, P. S., Blydt-Hansen, M., Takano, T., Ferreira, J. P., Tsoukas, M. A., Sharma, A., & Mavrakanas, T. A. (2025) · Cardiorenal Medicine · doi:10.1159/000546520 · Cited by 7
Teuber, J. P., Scissors, R. E., Subramani, A., Madamanchi, N. R., & Brody, M. J. (2025) · JCI Insight · doi:10.1172/jci.insight.193733 · Cited by 9
Virani, S., Zieroth, S. R., Aleksova, N., Anderson, K., Clarke, B., Ducharme, A., Ezekowitz, J. A., Foroutan, F., Giannetti, N., Jain, R., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.027 · Cited by 34
RetractedEffects of dual blockade in heart failure and renal dysfunction: Systematic review and meta-analysis
Silva, A. R., Martini, A. G., Canto, G. D. L., Guerra, E. N. S., & Neves, F. D. A. R. (2019) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320319882656 · Cited by 7
Shi, Y., Wang, Y., Chen, J., Lu, C., Xuan, H., Wang, C., Li, D., & Xu, T. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-140132 · Cited by 8
Arterial hypertension - clinical trials update 2022
Götzinger, F., Kunz, M., Lauder, L., Böhm, M., & Mahfoud, F. (2022) · Hypertension Research · doi:10.1038/s41440-022-00931-2 · Cited by 9
González, O. E. O., Mejía, D. C. L., Kaplinsky, E., Barbagelata, A., & Perrone, S. V. (2023) · Drugs in Context · doi:10.7573/dic.2022-6-4 · Cited by 8
Marques, I., Ramos, R. L., Mendonça, D. M., & Teixeira, L. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2022.07.017 · Cited by 11
Mapelli, M., Mattavelli, I., Salvioni, E., Bonomi, A., Capra, N., Palermo, P., Banfi, C., Paolillo, S., Biondi, M. L., & Agostoni, P. (2023) · Drugs in R&D · doi:10.1007/s40268-023-00438-2 · Cited by 7
Natriuretic peptide testing strategies in heart failure: A 2023 update
Chaikijurajai, T., Rincon-Choles, H., & Tang, W. H. W. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.11.005 · Cited by 11
Ajay, A., Rasoul, D., Abdullah, A., En, B. L. W., Mashida, K., Al-Munaer, M., Ajay, H., Duvva, D., Mathew, J., Adenaya, A., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2290064 · Cited by 8
Ezhumalai, B., Modi, R., Panchanatham, M., & Kaliyamoorthy, D. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.07.005 · Cited by 11
Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction
Palazzuoli, A., Severino, P., D’Amato, A., Myftari, V., Tricarico, L., Correale, M., Dattilo, G., Fioretti, F., & Nodari, S. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2507270 · Cited by 10
Pascual-Figal, D. A., & Bayés‐Genís, A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1439696 · Cited by 7
Aldosterone and Potassium in Heart Failure: Overcoming This Major Impediment in Clinical Practice
Khan, L. A., Jamil, A., Greene, S. J., Khan, M. S., & Butler, J. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.09 · Cited by 7
Berg, D. D., Patel, S. M., Haller, P. M., Bělohlávek, J., Desai, A. S., Dróżdż, J., Inzucchi, S. E., McMurray, J. J. V., Merkely, B. P., O’Meara, E., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.014 · Cited by 9
Camilli, M., Buono, M. G. D., Menna, P., & Minotti, G. (2020) · Cardio-Oncology · doi:10.1186/s40959-020-00083-7 · Cited by 7
Sacubitril/Valsartan Off-Label Uses for Heart Failure
Kido, K., Colvin, B. M., Szymanski, T. W., & Guglin, M. E. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.03.348 · Cited by 8
Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy
Murphy, D., & Banerjee, D. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00552-3 · Cited by 7
Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021
Lai, P., Xue, J., Xie, M.-J., Ye, J.-H., Tian, K.-J., Ling, J., Zhong, W.-T., Chen, D., Zhong, Y.-M., & Liao, Y.-L. (2022) · Medicine · doi:10.1097/md.0000000000029398 · Cited by 8
Gao, J., Zhao, C., Zhang, W., Liu, S., Xin, H., & Lian, Z. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10273-3 · Cited by 10
SGLT2 Inhibition in Acute Myocardial Infarction—A Comprehensive Review
Benedikt, M., Kolesnik, E., Sourij, H., & von Lewinski, D. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2402032 · Cited by 10
Nougue, H., Thibault, M., Picard, F., Lassus, J. P. E., Sadoune, M., Laribi, S., Solal, A. C., Logeart, D., Launay, J., & Vodovar, N. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvac225 · Cited by 9
Valli, F., Bursi, F., Santangelo, G., Toriello, F., Faggiano, A., Rusconi, I., Vella, A. M., Carugo, S., & Guazzi, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072659 · Cited by 10
Hypotension at heart failure discharge: Should it be a limiting factor for drug titration?
Melendo‐Viu, M., Dobarro, D., Marchán-López, Á., Domínguez, L. M., Raposeiras‐Roubín, S., Abu‐Assi, E., Cardero-González, C., Pérez-Expósito, L., Fernández, M. C., Barcía, J. A. P., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.05.007 · Cited by 9
Sacubitril/Valsartan and B-Type Natriuretic Peptide Value: Recalculating Route
Sequeiros, M. A., Díaz, S. D. P., del Rey, J. M., Salinas, G. L. A., & Zamorano, J. L. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1589 · Cited by 7
Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019
Leiva, O., Bhatt, A. S., & Vaduganathan, M. (2020) · Heart Failure Clinics · doi:10.1016/j.hfc.2020.06.004 · Cited by 7
Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
Rodriguez, J. B. C., Cu, C., & Siddiqui, T. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4038 · Cited by 6
Representation of Black patients in heart failure clinical trials
Azam, T. U., & Colvin, M. M. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000849 · Cited by 9
Liang, H.-W., Liao, C., Lin, W., Chung, F., Huang, J., Lee, Y., Lin, P.-L., Chiou, W., Hsu, C., & Chang, H. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000546 · Cited by 7
Lee, W., Chang, W., Hong, C., Liao, C., Huang, P.-S., Huang, S.-C., Lin, C., Chiang, C., Chen, Z., & Shih, J. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2804081 · Cited by 8
Metadata
- Authors
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 539-548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899841238
- Cited by
- 1,260
- References
- 16
- Citations by year
- 2026: 74 · 2025: 139 · 2024: 136 · 2023: 215 · 2022: 199 · 2021: 189 · 2020: 171 · 2019: 128
- FWCI
- 93.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- acute decompensated heart failure, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, NT-proBNP, renal function, hyperkalemia, angioedema, symptomatic hypotension, drug safety, hospitalization, hemodynamic stabilization, natriuretic peptides
- MeSH terms
- Valsartan, Acute Disease, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiac Output, Low, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Stroke Volume, Tetrazoles, Neprilysin, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.